About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 231 record(s)
Req # A-2019-001926
Adverse Drug Reactions (ADRs) for C1 Esterase Inhibitor (Human). Report numbers: E2B_02828986, E2B_02830392, E2B_02860921.Organization: Health Canada
March 2022
Req # A-2019-001962
Adverse Drug Reactions (ADRs). Report numbers: E2B_02469072, E2B_02850448.Organization: Health Canada
March 2022
Req # A-2019-002056
Adverse Drug Reactions (ADRs) for DEXILANT. Report numbers: E2B_02903597, E2B_02875816, E2B_02883292, E2B_02910452.Organization: Health Canada
March 2022
Req # A-2019-002074
Adverse Drug Reaction (ADR). Report number: E2B_02702475.Organization: Health Canada
March 2022
Req # A-2020-000008
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02349906, E2B_02503758, E2B_02508449, E2B_02502648, E2B_02567440, E2B_02524286, E2B_02525571, E2B_02524497E2 B_02575852, E2B_02577429.Organization: Health Canada
March 2022
Req # A-2020-000011
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02517328, E2B_02532424, E2B_02618445, E2B_02519466, E2B_02532431, E2B_02519521, E2B_02624954, E2B_02532555, E2B_02519814, E2B_02626821, E2B_02626957, E2B_02535896, E2B_02627276, E2B_02519890, E2B_02627431.Organization: Health Canada
March 2022
Req # A-2020-000013
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_02520701, E2B_02553852, E2B_02522837, E2B_02522878, E2B_02556526, E2B_02558426, E2B_02562252, E2B_02644842, E2B_02612592, E2B_02614536, E2B_02616387, E2B_02618760, E2B_02646771, E2B_02646824, E2B_02647003, E2B_02647205, E2B_02658337, E2B_00946890, E2B_00946890.Organization: Health Canada
March 2022
Req # A-2020-000053
Adverse Drug Reactions (ADRs) for ONDANSETRON. Report numbers: E2B_02972719, E2B_02974870, E2B_02962797, E2B_02972729, E2B_02974851, 000734877.Organization: Health Canada
March 2022
Req # A-2020-000085
Adverse Drug Reactions (ADRs) for Cipralex. Report numbers: 000728894, 000729810, E2B_02680873, E2B_02681008, E2B_02691752, E2B_02693264, E2B_02698395, E2B_02732952, E2B_02734774, E2B_02747299, E2B_02764074, E2B_02747441, E2B_02753947, E2B_02761076, E2B_02812121, E2B_02802564, E2B_02812115, E2B_02768927.Organization: Health Canada
March 2022
Req # A-2020-000088
Adverse Drug Reactions (ADRs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02762422, E2B_02727283, E2B_02670217, E2B_02806045, E2B_02727284, E2B_02727285, E2B_02727286, E2B_02728119, E2B_02728165, E2B_02728218, E2B_02763683, E2B_02783988, E2B_02769922, E2B_02773610, E2B_02781965.Organization: Health Canada
March 2022